Aileron Therapeutics (ALRN) IPO Opens Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Aileron Therapeutics Announces Pricing of Initial Public Offering
June 28, 2017 10:06 PM EDTCAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Aileron. In addition, Aileron has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock from the company at the public offering price. Ailerons common stock is... More
